Antibody therapy
First Claim
Patent Images
1. A method for treating a CEA and/or NCA expressing carcinoma comprising:
- a) administering to a subject with a CEA and/or NCA expressing carcinoma a monovalent Class I anti-CEA monoclonal antibody (MAb) or antigen-binding fragment thereof, wherein the MAb or fragment thereof is a monovalent chimeric or humanized MN-3 or MN-15 antibody; and
b) administering either concurrently or sequentially at least one anti-cancer therapeutic agent.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
71 Citations
18 Claims
-
1. A method for treating a CEA and/or NCA expressing carcinoma comprising:
-
a) administering to a subject with a CEA and/or NCA expressing carcinoma a monovalent Class I anti-CEA monoclonal antibody (MAb) or antigen-binding fragment thereof, wherein the MAb or fragment thereof is a monovalent chimeric or humanized MN-3 or MN-15 antibody; and b) administering either concurrently or sequentially at least one anti-cancer therapeutic agent. - View Dependent Claims (2, 3, 5, 6, 7, 8, 9, 10)
-
-
4. A method for treating a CEA and/or NCA expressing carcinoma comprising:
-
a) administering to a subject with a CEA and/or NCA expressing carcinoma a monovalent Class I anti-CEA monoclonal antibody (MAb) or antigen-binding fragment thereof, wherein said antibody fragment is selected from the group consisting of a Fab′
, a Fab, an Fv and an scFv; andb) administering either concurrently or sequentially at least one anti-cancer therapeutic agent. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18)
-
Specification